Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11299621 | 0.82 | SLC22A6 (0.33) | SLC22A6TDP1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11295122 | 0.80 | SLC22A6 (0.32) | SLC22A6TDP1SMN1; SMN2 | |
| SCHEMBL11295903 | 0.80 | SLC22A6 (0.32) | SLC22A6TDP1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11296962 | 0.79 | SLC22A6 (0.31) | SLC22A6TDP1 | |
| Hydrochloric Acid SCHEMBL11490820 | 0.76 | SMN1; SMN2 (0.39) | SLC22A6TDP1SMN1; SMN2GABRR1LMNA | |
| SCHEMBL6467551 | 0.76 | SLC22A6 (0.36) | SLC22A6TDP1SMN1; SMN2GABRR1LMNA | |
| SCHEMBL1262446 | 0.76 | SLC22A6 (0.50) | SLC22A6TDP1SMN1; SMN2GABRR1LMNA | |
| SCHEMBL6734706 | 0.73 | SLC22A6 (0.47) | SLC22A6TDP1SMN1; SMN2GABRR1LMNA | |
| SCHEMBL2037940 | 0.73 | SLC22A6 (0.38) | SLC22A6TDP1SMN1; SMN2GABRR1LMNA | |
| SCHEMBL8018447 | 0.73 | ALDH1A1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1930310-B1 | PROCESS FOR PRODUCING 3,3,3-TRIFLUOROPROPIONALDEHYDE | CENTRAL GLASS CO LTD (JP) | 2011-11-16 | — | — | EP | disclosed |
| US-20110263941-A1 | ENDOSCOPE DESIGNS AND METHODS OF MANUFACTURE | Intergrated Endoscopy,Inc. (US) | 2011-10-27 | — | — | US | disclosed |
| US-7544844-B2 | Process for producing 3,3,3-trifluoropropionaldehyde | CENTRAL GLASS COMPANY, LIMITED (JP) | 2009-06-09 | — | — | US | disclosed |
| US-20090105506-A1 | Process for Producing 3,3,3-Trifluoropropionaldehyde | CENTRAL GLASS COMPANY, LIMITED (JP) | 2009-04-23 | — | — | US | disclosed |
| EP-1930310-A1 | PROCESS FOR PRODUCING 3,3,3-TRIFLUOROPROPIONALDEHYDE | Central Glass Co., Ltd. (JP) | 2008-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105506-A1 | Process for Producing 3,3,3-Trifluoropropionaldehyde | ALDH1A3, ALDH7A1, ALDH1A1 | SLC22A6 4285/4885TDP1 2889/4885SMN1; SMN2 3248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.